Integer Holdings (ITGR)
(Delayed Data from NYSE)
$121.11 USD
+0.11 (0.09%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $121.11 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$121.11 USD
+0.11 (0.09%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $121.11 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
Why You Should Add Chemed (CHE) Stock to Your Portfolio Now
by Zacks Equity Research
Within Chemed's (CHE) VITAS business, management notes the recent admission trends to be consistently positive and this momentum is likely to continue.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) gains on strategic partnerships and international prospects.
Ecolab's New Aquanomic Enhances Laundry Operations at Hotels
by Zacks Equity Research
Ecolab's (ECL) new Aquanomic 2.0 Low-Temp Solid Laundry Program likely to boost Global Institutional segment.
Cerner (CERN) Strong on EHR Prospects, Competition Intense
by Zacks Equity Research
Cerner's (CERN) strong EHR prospects and global outlook aid the company; margins continue to decline.
Neogen's (NEOG) Listeria Right Now Gets Approval from AOAC
by Zacks Equity Research
Neogen's (NEOG) Listeria Right Now likely to prove beneficial in preventing food-borne diseases in the United States.
DaVita Healthcare Partners' New Facility Now in Los Angeles
by Zacks Equity Research
DaVita's (DVA) incessant efforts to upgrade services, global expansion initiatives and active acquisitions are impressive.
Here's Why You Should Hold AmerisourceBergen (ABC) Stock Now
by Zacks Equity Research
Strong performance in the World Courier Business is likely to provide AmerisourceBergen (ABC) a competitive edge in the MedTech space.
Masimo (MASI) Scales a 52-Week High: What's Driving It?
by Zacks Equity Research
Masimo's (MASI) solid guidance for 2018 and a broad product spectrum drive stock.
Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q4
by Zacks Equity Research
Myriad Genetics (MYGN) witnesses strong performances from GeneSight, EndoPredict, Vectra DA and Prolaris tests in Q4.
Avanos Medical (AVNS) Jumps: Stock Rises 5.5%
by Zacks Equity Research
Avanos Medical (AVNS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Medtronic (MDT) Q1 Earnings Beat on Growth in All Lines
by Zacks Equity Research
All major business groups of Medtronic (MDT) contribute to solid top-line growth at CER, which highlighted sustainability across groups and regions.
Is Integer Holdings (ITGR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ITGR) Outperforming Other Medical Stocks This Year?
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys (AMED) witnesses solid Medicare and non-Medicare revenues at Home Health and Hospice divisions. A favorable demographic trend bodes well.
Becton, Dickinson Hits at a 52-Week High: What's Driving It?
by Zacks Equity Research
Becton, Dickinson (BDX) gains on solid fiscal Q3 results; view impressive.
Accuray (ARAY) Earnings Beat in Q4, Gross Orders Rise Y/Y
by Zacks Equity Research
Accuray's (ARAY) flagship Radixact System drives Q4 results; overseas gains raise hope.
Intuitive Surgical Gains From Solid Q2 and Strong AI Exposure
by Zacks Equity Research
Intuitive Surgical's (ISRG) impressive second-quarter 2018, strength in robotics and AI trends buoy optimism.
CVS Health's PBM Selling Season Strong, Aetna Deal on Track
by Zacks Equity Research
A solid 2019 PBM selling season is a significant positive for CVS Health's (CVS) growth. The company completes more than 70% of its client renewals, almost in line with the prior-year level.
Amedisys (AMED) Grows on Robust Home Health, Personal Care
by Zacks Equity Research
Amedisys' (AMED) solid performance in Personal Care division is impressive. Plus, a favorable demographic trend and calculating buyouts bode well for the company.
ITGR or LMNX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. LMNX: Which Stock Is the Better Value Option?
Integra LifeSciences Codman Arm Strong, Competition Rife
by Zacks Equity Research
Integra LifeSciences' (IART) progress within its channel expansion strategy and Codman integration buoys investors' optimism on the stock.
Inogen's Solid Europe Business Shapes Q2, Prospects Bright
by Zacks Equity Research
Inogen's (INGN) Europe performance solid in Q2; guidance for 2018 encourages.
Surmodics' (SRDX) IVD Unit Boosts Growth, R&D Focus Solid
by Zacks Equity Research
Surmodics' (SRDX) strong focus on R&D to provide it a competitive edge in the MedTech space.
Boston Scientific to Expand Within PI Via VENITI Buyout
by Zacks Equity Research
Presence of venous obstructive disease visibly grows across the globe, indicating huge prospects for Boston Scientific (BSX) in the treatment market.
Here's Why You Should Dump DENTSPLY (XRAY) Stock Right Now
by Zacks Equity Research
DENTSPLY (XRAY) incurs goodwill and intangible impairment charge. A lowered guidance is a concern.
Zacks.com highlights: Turtle Beach, Integer Holdings and PCM
by Zacks Equity Research
Zacks.com highlights: Turtle Beach, Integer Holdings and PCM